Caris Life Sciences Launches Caris ChromoSeq Combining Whole Genome and Transcriptome Sequencing for Myeloid Malignancies

Caris Life Sciences has introduced Caris ChromoSeq, a new tumor profiling assay designed specifically for myeloid malignancies. The company describes the product as the first of its kind to combine whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) in a single test. This development aims to provide comprehensive genomic and transcriptomic insights into myeloid cancers, which include conditions such as leukemia and other blood-related malignancies.

The assay reportedly offers an extensive analysis of genetic alterations by examining both DNA and RNA from tumor samples. By integrating WGS and WTS, Caris ChromoSeq seeks to identify mutations, structural variants, gene fusions, and expression changes that may contribute to disease progression or treatment resistance. According to the company, this dual approach enables a more detailed understanding of the molecular drivers behind myeloid malignancies compared to traditional diagnostic methods.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 2, 2026

Author

GOAI